Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the topic of several other research reports. Bank of America lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $2.90 to $2.50 in a report on Thursday, June 20th. StockNews.com lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.83.

Esperion Therapeutics Stock Down 3.9 %

Shares of Esperion Therapeutics stock opened at $2.22 on Friday. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The stock has a market cap of $420.60 million, a price-to-earnings ratio of -2.24 and a beta of 1.00. The company’s fifty day moving average is $2.31 and its 200 day moving average is $2.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.42. The business had revenue of $137.74 million during the quarter, compared to the consensus estimate of $53.11 million. As a group, equities analysts anticipate that Esperion Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently made changes to their positions in ESPR. Herbst Group LLC acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $28,000. Private Portfolio Partners LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at about $30,000. CVI Holdings LLC acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $37,000. Simplicity Wealth LLC acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $44,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $50,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.